ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
2.480
-0.140 (-5.34%)
Jul 9, 2025, 9:55 AM - Market open
ReShape Lifesciences Revenue
ReShape Lifesciences had revenue of $1.11M in the quarter ending March 31, 2025, a decrease of -42.75%. This brings the company's revenue in the last twelve months to $7.18M, down -13.92% year-over-year. In the year 2024, ReShape Lifesciences had annual revenue of $8.01M, down -7.74%.
Revenue (ttm)
$7.18M
Revenue Growth
-13.92%
P/S Ratio
0.01
Revenue / Employee
$398,611
Employees
18
Market Cap
5.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.01M | -672.00K | -7.74% |
| Dec 31, 2023 | 8.68M | -2.56M | -22.79% |
| Dec 31, 2022 | 11.24M | -2.36M | -17.35% |
| Dec 31, 2021 | 13.60M | 2.30M | 20.36% |
| Dec 31, 2020 | 11.30M | -3.79M | -25.12% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
RSLS News
- 8 days ago - ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System - GlobeNewsWire
- 12 days ago - ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement - GlobeNewsWire
- 13 days ago - ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys - GlobeNewsWire
- 14 days ago - ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology - GlobeNewsWire
- 27 days ago - ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets - GlobeNewsWire
- 4 weeks ago - ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering - GlobeNewsWire
- 5 weeks ago - ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio - GlobeNewsWire
- 7 weeks ago - ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update - GlobeNewsWire